What Nurses Need to Know About GU Malignancies
At the 3rd annual School of Oncology Nursing Laura S. Wood, RN, MSN, OCN, renal cancer research coordinator at the Cleveland Clinic Taussig Cancer Center and one of the co-chairs of the School of Oncology Nursing, presented on supportive care for GU malignancies and we had the chance to discuss the highlights with her.
At the 3rd annual School of Oncology Nursing, Oncology Nursing News® had the chance to sit down with Laura S. Wood, RN, MSN, OCN, renal cancer research coordinator at the Cleveland Clinic Taussig Cancer Center and one of the co-chairs of the School of Oncology Nursing, and discuss her presentation on GU malignancies highlighting one of the most important takeaways from the presentation.
TRANSCRIPTION
So as far as a presentation on GU malignancies and supportive care, I think it's important for nurses to take home the awareness that bone metastasis is a challenge, it does occur, and we need to make sure we assess and intervene early in order to minimize the negative impact it has on a patient. If we can control their systemic disease, the challenge is bones and brain are oftentimes more sanctuary sights and may not have the same benefit from therapy. So, we need to be astute in our assessment and awareness of these potential sites for metastasis and make sure we're intervening early because there are definitely advances in the options to treat those problems.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
